A retrospective analysis of allogeneic stem cell transplantation for peripheral T-cell lymphoma

Anne-Claire Mamez and colleagues examined the outcomes of allo-HSCT in patients with non-primary...

Comparison of reduced intensity conditioning regimens for allo-HSCT in patients with ALL

The results of a retrospective study comparing the effect of three commonly used reduced intensity conditioning...

The protective role of short-chain fatty acids from the development of GvHD

In a recent study Mathilde Payen and colleagues aimed to determine whether changes in the microbiome composition with...

Two different treatment approaches in combination with ECP for the management of steroid refractory aGvHD: etanercept and ruxolitinib

Two different studies have recently reported results using...

EHA 2020 | Phase III GRAVITAS-301 trial results on itacitinib plus corticosteroids for aGvHD

The results from the phase III GRAVITAS-301 trial that investigated the efficacy of the Janus kinase 1...

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

An interview from the 25th Congress of the EHA with Robert Zeiser, Medical Center – University of Freiburg,...

Subgroup analysis of ruxolitinib in patients with steroid-refractory acute GvHD – update from EHA 2020

A follow-up analysis of the REACH2 study, which examined responses in different subgroups of...

What factors impact response to mesenchymal stromal cells in patients with acute GvHD?

During the 25th Congress of the EHA, the GvHD Hub spoke to Antonio Galleu, King's College London. We asked: What...

A retrospective analysis of allogeneic stem cell transplantation for peripheral T-cell lymphoma

Anne-Claire Mamez and colleagues examined the outcomes of allo-HSCT in patients with non-primary...

Comparison of reduced intensity conditioning regimens for allo-HSCT in patients with ALL

The results of a retrospective study comparing the effect of three commonly used reduced intensity conditioning...

The protective role of short-chain fatty acids from the development of GvHD

In a recent study Mathilde Payen and colleagues aimed to determine whether changes in the microbiome composition with...

Ixazomib for advanced chronic GvHD: Results of a phase II trial

Joseph Pidala et al recently published the results of their phase II trial in which they examined the safety, clinical efficacy, and...